We are live on ! Find out more
CLRBZ

Cellectar Biosciences, Inc. Series A Warrants
CLRBZ

Delisted

CLRBZ was delisted on the 16th of April, 2021.

Back to rankings

1 hedge funds and large institutions have $1K invested in Cellectar Biosciences, Inc. Series A Warrants in 2018 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% less funds holding

Funds holding: 2 → 1 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

98% less capital invested

Capital invested by funds: $41K → $1K (-$40K)

Holders
1
Holders Change
-1
Holders Change %
-50%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$1.73K

Top Sellers

Rank Fund Capital Flow
1
CH
CVI Holdings
Delaware
-$39K
2
VF
Virtu Financial
New York
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$1K +$1.73K +14,674 New
CH
2
CVI Holdings
Delaware
– -$39K -207,500 Closed
VF
3
Virtu Financial
New York
– -$2K -11,892 Closed

CLRBZ Hedge Fund Activity: Q3 2018 in Review

1 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences, Inc. Series A Warrants (CLRBZ) for Q3 2018, worth a combined $1K — down 98% from $41K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of CLRBZ and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest buyer was UBS Group, opening a new position worth an estimated $1.73K. The largest seller was CVI Holdings, exiting entirely with an estimated $39K sold.

  • 1 institutional investor held Cellectar Biosciences, Inc. Series A Warrants (CLRBZ) as of Q3 2018, down from 2 in Q2 2018.
  • Funds reported $1K of Cellectar Biosciences, Inc. Series A Warrants stock for Q3 2018, down 98% quarter-over-quarter.
  • 1 fund opened new Cellectar Biosciences, Inc. Series A Warrants positions in Q3 2018 and 2 closed out, a net change of -1 holder.
  • The largest Cellectar Biosciences, Inc. Series A Warrants buyer in Q3 2018 was UBS Group, an estimated $1.73K added.
  • The largest Cellectar Biosciences, Inc. Series A Warrants seller in Q3 2018 was CVI Holdings, an estimated $39K sold.

Based on aggregated 13F filings for Q3 2018.